Living up to this law of nature, the tiny country of Estonia continues to punch above its weight. The country’s uniquely entrepreneurial environment, solid scientific and research foundation, and strongly interconnected scientific community provide the perfect backdrop for breakthroughs ranging from Europe’s first CE-marked cancer polygenic risk score tests to viral transport solution technology that enables direct real-time PCR without the need of any nucleic acid extraction or purification methods.
Meet the leading-edge biotech companies participating at BIO International Convention 2024 and pushing boundaries with their in-depth knowledge and constant drive to improve the world through science.
Gearbox Biosciences provides a novel antibiotic-free protein production technology in E. coli. Our strains do not require antibiotics or small-molecule inducers like IPTG, but produce proteins at high levels. This will reduce regulatory scrutiny and help the protein producers to cut costs – waste management is easier and there is no need to worry about antibiotic resistance gene contamination.
Cancer immunotherapy activates our immune system against tumor. This can be executed by sending an mRNA message to the immune cells. Up to now, the key limitation has been the transport of therapeutic mRNA into the patients. Vectiopep has developed a unique technology that achieves unprecedented selectivity in transporting mRNA to the patient’s immune cells. We will out-license our technology to the pharmaceutical companies to be used as a component in an oncology drug.
Icosagen, a leading CRDMO for the biopharmaceutical, biotechnology, and diagnostic industries, was founded in 1999. In 2022, we worked with 100+ companies, producing 3000+ proteins. Our seamless services include early clinical candidate development and stable CHO cell line development for 50L to 1000L GMP production runs. Clients trust us for custom-tailored solutions in every stage of drug development, from complicated protein discovery to recombinant production.
Chemestmed Ltd. has developed proprietary technologies and drug candidates based on the therapeutically targeted regulation of the RNA 6-methyladenosine (m6A) level in cells. Those include: (a) Activators of the RNA m6A methylation and their application in the case of neurodegenerative, neuropsychiatric and metabolic disorders, (b) Inhibitors of RNA m6A methyltransferase METTL16, RNA m6A demethylase AlkBH5 and RNA m6A demethylase FTO against cancer and neurodegeration (AlkBH5, FTO).
+372 503 4500[email protected]
Employing their patented halospinning technology, Gelatex is a pioneer in the high-speed production of nanofibrous materials. Halospinning is the world’s fastest and most efficient nanofiber technology reducing production costs up to 90%. Gelatex’s nanofibrous scaffolds replicate the natural cell growth environment advancing 3D cell culture and tissue engineering. The versatility of nanofibers extends to diverse applications, including controlled drug delivery, wound care, and regenerative medicine.
Bioatlas has been focusing on PCR and agarose gel electrophoresis for 15 years already. Still, our main aim is to revolutionize agarose gel preparation around the world with the help of our partners. We are looking for distribution partners, OEM resellers and scientific partners to meet our goals. Currently our main goal is to introduce safe DNA stains to every lab around the world. Our patented tablet format makes it even more appealing.
03 Jun 2024
San Diego Convention Center, California